MOLECULAR MECHANISMS UNDERLYING THE CARDIO- AND NEPHROPROTECTIVE EFFECTS OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS: A SYSTEMATIC REVIEW
Keywords:
SGLT2 inhibitors; GLP-1 receptor agonists; Cardioprotection; Nephroprotection; Tubuloglomerular feedback; Myocardial energetics; Endothelial dysfunction.Abstract
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the therapeutic landscape of type 2 diabetes mellitus (T2DM), heart failure (HF), and chronic kidney disease (CKD). Beyond their primary glucose-lowering actions, both drug classes exert profound organ-protective effects.
Objective: This systematic review synthesizes current evidence on the molecular, cellular, and physiological mechanisms driving the cardio- and nephroprotective outcomes of SGLT2i and GLP-1RAs.
Methods: A systematic literature search was conducted across PubMed/MEDLINE, Scopus, and Web of Science databases following PRISMA guidelines for studies published between 2018 and 2026.
Results: SGLT2i act primarily via hemodynamic restoration, reducing intraglomerular pressure through tubuloglomerular feedback (TGF), shifting myocardial energetics toward ketone utilization, inhibiting Na⁺/H⁺ exchanger 1 and 3 (NHE1/NHE3), and suppressing renal/cardiac inflammation and fibrosis. GLP-1RAs act predominantly via anti-inflammatory pathways, endothelial protection, reduction of oxidative stress, inhibition of vascular smooth muscle cell proliferation, and attenuation of renal hyperfiltration via systemic anti-atherosclerotic pathways.
Conclusion: SGLT2i and GLP-1RAs display distinct yet complementary molecular pathways. Their synergistic mechanism provides a strong rationale for combined therapy to achieve optimal cardiorenal protection in clinical practice.
References
1.Packer, M. (2020). Mutual antagonism of SGLT2 inhibitors and GLP-1 receptor agonists on renal sodium and glucose transport: physiological mechanisms and clinical implications. Circulation, 142(11), 1029-1031.
2.Heerspink, H. J., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436-1446.
3.Kristensen, S. L., et al. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet Diabetes & Endocrinology, 7(10), 776-785.
4.Zelniker, T. A., & Braunwald, E. (2020). Mechanisms of cardiorenal protection with SGLT2 inhibitors and GLP-1 receptor agonists. Journal of the American College of Cardiology, 75(4), 435-447.
5.Mann, J. F., et al. (2017). Liraglutide and renal outcomes in type 2 diabetes. New England Journal of Medicine, 377(9), 839-848.
6.American Diabetes Association (ADA). (2025). Standards of Care in Diabetes—2025: Cardiovascular Disease and Risk Management. Diabetes Care, 48(Suppl. 1), S180–S210.
7.European Society of Cardiology (ESC) & EASD Task Force. (2025/2026). Focused Update on Cardiorenal Protection in Type 2 Diabetes and Chronic Kidney Disease. European Heart Journal, 47(3), 215–228.
8.Verma, S., & McMurray, J. J. (2018). SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 61(10), 2108-2117.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal